

REMARKS

Claims 1, 4-8, 11, 13-16, 18-22, 28-30, 36-44, 46, 48, 50-59, 61-66, 70-72, 74, 76-78, 83, 85, 88, 91-95, 98-100 and 133-137 are pending. Claims 2, 3, 9-12, 17, 23-27, 31-35, 45, 47, 49, 60, 67-69, 73, 75, 79-82, 84-87, 89, 90, 96, 97, 101-132 and 138-139 have been cancelled.

Reconsideration of the pending claims in view of the amendments above and remarks below is respectfully requested.

Sequence listing

This submission supplements the previous response filed on March 9, 2006.

In the previous submission, Applicants provided a substitute paper copy of the Sequence Listing, pages 1-25, and substitute computer readable form (labeled "CRF") of the Sequence Listing in CD-R format, in compliance with 37 C.F.R. §1.821(c), and §1.825(a) and (b). The substitute sheets of the Sequence Listing and the substitute computer readable form labeled "CRF" submitted contained no new matter. Sequence number 79 was added to the sequences listing to comply with the rules. This sequence was provided in original claim 137 as filed. Claim 137 was also amended to include the new SEQ ID number which was inadvertently omitted at the time of filing. Additionally, the paragraph on page 32, beginning at line 1 was also amended to include a sequence identification number which was inadvertently omitted at the time the application was filed. Correction of this omission does not constitute the addition of new matter as the peptide sequence was present at the time the application was filed.

CONCLUSION

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 278012001420. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June 27, 2006

Respectfully submitted,

By 

James J. Mullen III, Ph.D.

Registration No.: 44,957

MORRISON & FOERSTER LLP

12531 High Bluff Drive, Suite 100

San Diego, California 92130

(858) 720-7940